Haemophilus meningitis

Last updated
Haemophilus meningitis
Specialty Neurology   OOjs UI icon edit-ltr-progressive.svg

Haemophilus meningitis is a form of bacterial meningitis caused by the Haemophilus influenzae bacteria. It is usually (but not always) associated with Haemophilus influenzae type b. [1] Meningitis involves the inflammation of the protective membranes that cover the brain and spinal cord. Haemophilus meningitis is characterized by symptoms including fever, nausea, sensitivity to light, headaches, stiff neck, anorexia, and seizures. [2] [3] Haemophilus meningitis can be deadly, but antibiotics are effective in treating the infection, especially when cases are caught early enough that the inflammation has not done a great deal of damage. [2] Before the introduction of the Hib vaccine in 1985, [4] Haemophilus meningitis was the leading cause of bacterial meningitis in children under the age of five. However, since the creation of the Hib vaccine, only two in every 100,000 children contract this type of meningitis. [2] Five to ten percent of cases can be fatal, [5] although the average mortality rate in developing nations is seventeen percent, [3] mostly due to lack of access to vaccination as well as lack of access to medical care needed to combat the meningitis.

Contents

Symptoms and signs

Possible symptoms of Haemophilus meningitis include: [2] [3]

Risk factors

While the Haemophilus influenzae bacteria are unable to survive in any environment outside of the human body, humans can carry the bacteria within their bodies without developing any symptoms of the disease. It spreads through the air when an individual carrying the bacteria coughs or sneezes. [4] The risk of developing Haemophilus meningitis is most directly related to an individual's vaccination history, as well as the vaccination history of the general public. Herd immunity, or the protection that unvaccinated individuals experience when the majority of others in their proximity are vaccinated, does help in the reduction of meningitis cases, but it does not guarantee protection from the disease. [3] Contact with other individuals with the disease also vastly increases the risk of infection. A child in the presence of family members sick with Haemophilus meningitis or carrying the bacteria is 585 times more likely to catch Haemophilus meningitis. [6] Additionally, siblings of individuals with the Haemophilus influenzae meningitis receive reduced benefits from certain types of immunization. [7] Similarly, children under two years of age have a greater risk of contracting the disease when attending day care, especially in their first month of attendance, due to the maintained contact with other children who might be asymptomatic carriers of the Hib bacteria. [3]

Diagnosis

Prevention

Before the widespread use of the Hib vaccine, Haemophilus meningitis accounted for 40%-60% of all meningitis cases in children under the age of fifteen, and 90% of all meningitis cases in children under the age of five. [3] Vaccination can reduce incidence. [8] Vaccination has reduced the occurrences of Haemophilus meningitis by 87-90% in countries with widespread access to the Hib vaccine. [3] Rates are still high in areas with limited levels of vaccination. [9] Less-developed countries as well as countries with medical infrastructure that has been damaged in any way, such as from warfare, do not have such widespread access to the vaccine and thus experience higher rates of meningitis cases. Multiple conjugate Hib vaccines are available for use, though, and are extremely effective when given to infants. [5] Additionally, the vaccine has only the side effects of reddened skin and swelling at the location of the injection. [5]

Treatment

Because it is a bacterial disease, the primary method of treatment for Haemophilus meningitis is anti-bacterial therapy. Common antibiotics include ceftriaxone [2] [3] or cefotaxime, both of which can combat the infection and thus reduce inflammation in the meninges, or the membranes that protect the brain and spinal cord. Anti-inflammatories such as corticosteroids, or steroids produced by the body to reduce inflammation, can also be used to fight the meningeal inflammation in an attempt to reduce risk of mortality and reduce the possibility of brain damage.[ citation needed ]

Prognosis

Survivors of Haemophilus meningitis may experience permanent damage caused by inflammation around the brain, mostly involving neurological disorders. Long-term complications include brain damage, hearing loss, and mental disability. [5] Other possible long-term effects are reduced IQ, cerebral palsy, and the development of seizures. [10] Children that survive the disease are more often held back in school, and are more likely to require special education services. [10] Negative long-term effects are more likely in subjects whose treatments were delayed, as well as in subjects who were given antibiotics to which the bacteria was resistant. [3] Ten percent of survivors develop epilepsy, while close to twenty percent of survivors develop hearing loss ranging from mild loss to deafness. About 45% of survivors experience no negative long-term effects. [3]

Related Research Articles

<span class="mw-page-title-main">Pneumonia</span> Inflammation of the alveoli of the lungs

Pneumonia is an inflammatory condition of the lung primarily affecting the small air sacs known as alveoli. Symptoms typically include some combination of productive or dry cough, chest pain, fever, and difficulty breathing. The severity of the condition is variable.

<span class="mw-page-title-main">Mumps</span> Human disease caused by paramyxovirus

Mumps is a viral disease caused by the mumps virus. Initial symptoms are non-specific and include fever, headache, malaise, muscle pain, and loss of appetite. These symptoms are usually followed by painful swelling of the parotid glands, called parotitis, which is the most common symptom of infection. Symptoms typically occur 16 to 18 days after exposure to the virus and resolve within two weeks. About one third of infections are asymptomatic.

<span class="mw-page-title-main">Waterhouse–Friderichsen syndrome</span> Medical condition

Waterhouse–Friderichsen syndrome (WFS) is defined as adrenal gland failure due to bleeding into the adrenal glands, commonly caused by severe bacterial infection. Typically, it is caused by Neisseria meningitidis.

<i>Streptococcus pneumoniae</i> Species of bacterium

Streptococcus pneumoniae, or pneumococcus, is a Gram-positive, spherical bacteria, alpha-hemolytic or beta-hemolytic, aerotolerant anaerobic member of the genus Streptococcus. They are usually found in pairs (diplococci) and do not form spores and are non motile. As a significant human pathogenic bacterium S. pneumoniae was recognized as a major cause of pneumonia in the late 19th century, and is the subject of many humoral immunity studies.

<i>Haemophilus influenzae</i> Species of bacterium

Haemophilus influenzae is a Gram-negative, non-motile, coccobacillary, facultatively anaerobic, capnophilic pathogenic bacterium of the family Pasteurellaceae. The bacteria are mesophilic and grow best at temperatures between 35-37℃.

Asplenia refers to the absence of normal spleen function and is associated with some serious infection risks. Hyposplenism is used to describe reduced ('hypo-') splenic functioning, but not as severely affected as with asplenism.

<span class="mw-page-title-main">Bacterial pneumonia</span> Disease of the lungs

Bacterial pneumonia is a type of pneumonia caused by bacterial infection.

<span class="mw-page-title-main">Epiglottitis</span> Inflammation of the epiglottis

Epiglottitis is the inflammation of the epiglottis—the flap at the base of the tongue that prevents food entering the trachea (windpipe). Symptoms are usually rapid in onset and include trouble swallowing which can result in drooling, changes to the voice, fever, and an increased breathing rate. As the epiglottis is in the upper airway, swelling can interfere with breathing. People may lean forward in an effort to open the airway. As the condition worsens stridor and bluish skin may occur.

<span class="mw-page-title-main">Conjugate vaccine</span> Type of vaccine

A conjugate vaccine is a type of subunit vaccine which combines a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

Community-acquired pneumonia (CAP) refers to pneumonia contracted by a person outside of the healthcare system. In contrast, hospital-acquired pneumonia (HAP) is seen in patients who have recently visited a hospital or who live in long-term care facilities. CAP is common, affecting people of all ages, and its symptoms occur as a result of oxygen-absorbing areas of the lung (alveoli) filling with fluid. This inhibits lung function, causing dyspnea, fever, chest pains and cough.

<span class="mw-page-title-main">Childhood immunizations in the United States</span>

The schedule for childhood immunizations in the United States is published by the Centers for Disease Control and Prevention (CDC). The vaccination schedule is broken down by age: birth to six years of age, seven to eighteen, and adults nineteen and older. Childhood immunizations are key in preventing diseases with epidemic potential.

<span class="mw-page-title-main">Meningococcal disease</span> Medical condition

Meningococcal disease describes infections caused by the bacterium Neisseria meningitidis. It has a high mortality rate if untreated but is vaccine-preventable. While best known as a cause of meningitis, it can also result in sepsis, which is an even more damaging and dangerous condition. Meningitis and meningococcemia are major causes of illness, death, and disability in both developed and under-developed countries.

<span class="mw-page-title-main">Hattie Alexander</span> American pediatrician and microbiologist

Hattie Elizabeth Alexander was an American pediatrician and microbiologist. Hattie earned her M.D. from Johns Hopkins University in 1930 and continued her research and medical career at Columbia-Presbyterian Hospital in New York City. She became the lead microbiologist and the head of the bacterial infections program at Columbia-Presbyterian. Alexander occupied many prestigious positions at Columbia University and was well honored even after her death from liver cancer in 1968. She is known for her development of the first effective remedies for Haemophilus influenzae infection, as well as being one of the first scientists to identify and study antibiotic resistance. Hattie has received many awards and honors including the E. Mead Johnson Award in 1942, for her headway in pediatric research and antibiotic resistance. Her research and studies helped lay the ground work for research into antibiotic and vaccine development.

<span class="mw-page-title-main">Hib vaccine</span> Haemophilus influenzae type B vaccine

The Haemophilus influenzae type B vaccine, also known as Hib vaccine, is a vaccine used to prevent Haemophilus influenzae type b (Hib) infection. In countries that include it as a routine vaccine, rates of severe Hib infections have decreased more than 90%. It has therefore resulted in a decrease in the rate of meningitis, pneumonia, and epiglottitis.

John Bennett Robbins was a senior investigator at the National Institutes of Health (NIH), best known for his contribution to the development of the vaccine against bacterial meningitis with his colleague Rachel Schneerson. He conducted research on the Bethesda, Maryland campus of the NIH from 1970 until his retirement at the age of 80 in 2012. During his tenure, he worked in the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the Food and Drug Administration’s biologics laboratories on location.

A pneumococcal infection is an infection caused by the bacterium Streptococcus pneumoniae, which is also called the pneumococcus. S. pneumoniae is a common member of the bacterial flora colonizing the nose and throat of 5–10% of healthy adults and 20–40% of healthy children. However, it is also a cause of significant disease, being a leading cause of pneumonia, bacterial meningitis, and sepsis. The World Health Organization estimates that in 2005 pneumococcal infections were responsible for the death of 1.6 million children worldwide.

<span class="mw-page-title-main">Meningitis</span> Inflammation of the membranes around the brain and spinal cord

Meningitis is acute or chronic inflammation of the protective membranes covering the brain and spinal cord, collectively called the meninges. The most common symptoms are fever, headache, and neck stiffness. Other symptoms include confusion or altered consciousness, nausea, vomiting, and an inability to tolerate light or loud noises. Young children often exhibit only nonspecific symptoms, such as irritability, drowsiness, or poor feeding. A non-blanching rash may also be present.

A vaccine-preventable disease is an infectious disease for which an effective preventive vaccine exists. If a person acquires a vaccine-preventable disease and dies from it, the death is considered a vaccine-preventable death.

<span class="mw-page-title-main">Neonatal meningitis</span> Medical condition

Neonatal meningitis is a serious medical condition in infants that is rapidly fatal if untreated. Meningitis is an inflammation of the meninges, the protective membranes of the central nervous system, is more common in the neonatal period than any other time in life, and is an important cause of morbidity and mortality globally. Mortality is roughly half in developing countries and ranges from 8%-12.5% in developed countries.

<span class="mw-page-title-main">Rachel Schneerson</span> Israeli-American vaccinologist

Rachel Schneerson is a former senior investigator in the Laboratory in Developmental and Molecular Immunity and head of the Section on Bacterial Disease Pathogens and Immunity within the Laboratory at the Eunice Kennedy Shriver National Institute of Child Health and Human Development within the National Institutes of Health. She is best known for her development of the vaccine against bacterial meningitis with her colleague John B. Robbins.

References

  1. ↑ Al-Tawfiq JA (2007). "Haemophilus influenzae type e meningitis and bacteremia in a healthy adult". Intern. Med. 46 (4): 195–8. doi: 10.2169/internalmedicine.46.1807 . PMID   17301516.
  2. 1 2 3 4 5 "Meningitis - H. influenzae". MedlinePlus. U.S. National Library of Medicine. Retrieved 23 October 2014.
  3. 1 2 3 4 5 6 7 8 9 10 Haran Chandrasekar, Pranatharthi; Cavaliere, Robert; Stanley Rust Jr, Robert; Swaminathan, Subramanian. "Haemophilus Meningitis". Medscape. Retrieved 28 October 2014.
  4. 1 2 "Haemophilus influenzae type b (Hib)". The History of Vaccines. The College of Physicians of Philadelphia. Retrieved 12 November 2014.
  5. 1 2 3 4 "Haemophilus influenzae type b (Hib)". World Health Organization. World Health Organization. Archived from the original on April 20, 2006. Retrieved 30 October 2014.
  6. ↑ Ward JI, Fraser DW, Baraff LJ, Plikaytis BD (July 1979). "Haemophilus influenzae meningitis. A national study of secondary spread in household contacts". N. Engl. J. Med. 301 (3): 122–6. doi:10.1056/NEJM197907193010302. PMID   313003.
  7. ↑ Granoff DM, Squires JE, Munson RS, Suarez B (August 1983). "Siblings of patients with Haemophilus meningitis have impaired anticapsular antibody responses to Haemophilus vaccine". J. Pediatr. 103 (2): 185–91. doi:10.1016/s0022-3476(83)80342-4. PMID   6603504.
  8. ↑ Miranzi Sde S, de Moraes SA, de Freitas IC (July 2007). "Impact of the Haemophilus influenzae type b vaccination program on HIB meningitis in Brazil". Cad Saude Publica. 23 (7): 1689–95. doi: 10.1590/s0102-311x2007000700021 . PMID   17572819.
  9. ↑ Minz S, Balraj V, Lalitha MK, Murali N, Cherian T, Manoharan G, Kadirvan S, Joseph A, Steinhoff MC (July 2008). "Incidence of Haemophilus influenzae type b meningitis in India". Indian J. Med. Res. 128 (1): 57–64. PMID   18820360.
  10. 1 2 D'Angio CT, Froehlke RG, Plank GA, Meehan DJ, Aguilar CM, Lande MB, Hugar L (September 1995). "Long-term outcome of Haemophilus influenzae meningitis in Navajo Indian children". Arch Pediatr Adolesc Med. 149 (9): 1001–8. doi:10.1001/archpedi.1995.02170220067009. PMID   7655584.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.